Jagsonpal Pharma H1FY27 PAT up 10.3% to ₹258 Mn; Consolidated Revenue Grows 29% to ₹964 Mn
Jagsonpal Pharmaceuticals reported H1FY27 PAT up 10.3% to ₹258 Mn and Q2FY27 consolidated revenue grew 29% to ₹964 Mn. Standalone revenue rose 9.3% in Q2 and 9.0% in H1. The company holds ₹1,347 Mn cash and has completed two acquisitions, aiming for ₹5,000 Mn revenue by 2028.
The announcement details robust financial performance, strategic acquisitions, and a clear roadmap for future growth, which are material factors for investors.
The company reported significant revenue growth, profit increase, and a strong cash position. Strategic acquisitions and clear future revenue targets contribute to a positive outlook.
Jagsonpal Pharmaceuticals Limited announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a consolidated revenue growth of 29% to ₹964 million in Q2FY27, with the standalone business contributing a 9.3% increase. For the half-year ended H1FY27, the net profit grew by 10.3%, driven by organic momentum across its key brands.
Standalone financial performance for Q2FY27 showed revenue at ₹814 million (up 9.3% YoY), EBITDA at ₹185 million (22.7% margin), and PAT at ₹126 million (15.5% margin). For H1FY27, standalone revenue stood at ₹1,636 million (up 9.0% YoY), EBITDA at ₹375 million (22.9% margin), and PAT at ₹258 million (15.8% margin). The company maintained a strong cash position of ₹1,347 million as of September 30, 2026, after an enhanced dividend payout of 200% in September.
Jagsonpal has been actively pursuing inorganic growth, consolidating an 85% stake in Aequitas Healthcare for ₹208 million in an all-cash deal, which opened up access to over 1,000 hospitals. The acquisition of the Group Pharma Wellness Portfolio was completed on October 1, 2026, further strengthening its wellness offerings. These strategic investments, including a strengthened hospital team and marketing inputs, are expected to reflect in profitability from Q3FY27 onwards.
Mr. Manish Gupta, Managing Director and CEO, expressed confidence in the company's growth trajectory, expecting quarterly revenues to cross ₹1,000 million in Q3FY27 and reiterating the Mission 2028 target of ₹5,000 million in annual revenue. He highlighted the company's strong cash balance and a proven track record of inorganic growth as drivers for future value creation.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.